Please login to the form below
Dificid
This page shows the latest Dificid news and features for those working in and with pharma, biotech and healthcare.
After delay, Merck gets US approval for serious infection drug
GlobalData says Merck will lead the market thanks to Dificid/Dificlir (fidaxomicin), which it predicts will be the biggest-selling antibiotic for these infections, while Zinplava could see competition in the
Latest news
-
EC approves first-in-class antibiotic Dificlir
Fidaxomicin was approved in the US earlier this year where it is sold as Dificid.
-
Optimer antibiotic approved
difficile-associated diarrhoea.". In clinical trials, Dificid worked as well as ViroPharma's Vancocin (vancomycin) in curing CDAD and was better than vancomycin at preventing recurrence of infection. ... Dificid, which is Optimer's first approved product,
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during December 2014
The Optimer acquisition brought to Cubist an approved antibacterial drug for the treatment of Clostridium difficile-associated diarrhoea (CDAD) called DIFICID (fidaxomicin).
-
Deal Watch table for July 2013
815. Optimer Pharmaceuticals / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline based on Dificid (fidaxomicin) for C.difficile (approved).
-
Pharma deals during July 2013
Cubist had already developed a relationship with Optimer through their 2011 co-promotion agreement for Dificid (fidaxomicin), for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in adults 18 years of ... Dificid was launched in the US
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Former Pfizer CEO Henry McKinnell appointed CEO of Optimer
Commenting on his appointment as Optimer's CEO, Dr McKinnell acknowledged the company's current compliance issues as well as the 2011 launch of the company's lead product antibiotic ... utilisation of Dificid.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
